Advertisement

Surgical Treatment of Meniere’s Disease

  • Neal M. Jackson
  • Michael J. LaRouere
Chapter

Abstract

Meniere’s disease was first described by Prosper Meniere in 1861 [1]. The classic disease description includes the tetrad of hearing loss, tinnitus, aural fullness, and vertigo spells. The disease tends to fluctuate and can be said to be predictably unpredictable. The spells can last from minutes to hours. Attacks can be associated with nausea, vomiting, headache, and fatigue. Medical management is sufficient for a majority of patients, but those who are recalcitrant may be a candidate for surgical intervention. Currently, a variety of surgical techniques are employed for patients with Meniere’s disease who have failed medical treatment.

Keywords

Vertigo Meniere’s disease Surgery 

References

  1. 1.
    Meniere P. Sur une forme de surdite grave dependant d’une lesion de l’oreille interne. Gaz Med de Paris. 1861;16:29.Google Scholar
  2. 2.
    Dandy W. Effects on hearing after subtotal section of the cochlear branch of the auditory nerve. Bull Johns Hopkins Hosp. 1934;55:240–3.Google Scholar
  3. 3.
    Dandy W. The surgical treatment of Ménière’s disease. Surg Gynecol Obstet. 1941;72:421–5.Google Scholar
  4. 4.
    Lake R. Removal of semicircular canals in a case of unilateral aural vertigo. Lancet. 1904;1:421.Google Scholar
  5. 5.
    Cawthorne TE. The treatment of Ménière’s disease. J Laryngol Otol. 1943;58:363–71.CrossRefGoogle Scholar
  6. 6.
    Portmann G. Vertigo, surgical treatment of opening of the saccus endolymphaticus. Arch Otolarygol Head Neck Surg. 6:309–19.Google Scholar
  7. 7.
    House WF. Subarachnoid shunt for drainage of endolymphatic hydrops. Laryngoscope. 1962;72:713–29.PubMedGoogle Scholar
  8. 8.
    Schuknecht HF. Cochlear endolymphatic shunt. Am J Otol. 1984;5:546–8.PubMedGoogle Scholar
  9. 9.
    Pou AM, Hirsch BE, Durrant JD, et al. The efficacy of tympanic electrocochleography in diagnosis of endolymphatic hydrops. Am J Otol. 1996;17(4):607–11.PubMedGoogle Scholar
  10. 10.
    Fischer LM, Derebery J. Oral steroid treatment for hearing improvement in Ménière’s disease and endolymphatic hydrops. Otol Neurotol. 2012;33(9):1685–91.CrossRefGoogle Scholar
  11. 11.
    Balkany. The bilateral aspects of Meniere’ disease: an underestimated entity. Otolaryngol Clin N Am. 1980;12:603–9.Google Scholar
  12. 12.
    Shea JJ Jr. The role of dexamethasone or streptomycin perfusion in the treatment of Ménière’s disease. Otolaryngol Clin N Am. 1997;30(6):1051.Google Scholar
  13. 13.
    Parnes LS, Sun AH, Freeman DJ. Corticosteroid pharmacokinetics in the inner ear fluids: an animal study followed by clinical application. Laryngoscope. 1999;109:1–17.CrossRefGoogle Scholar
  14. 14.
    Chandrasekhar SS, Rubinstein RY, Kwartler JA. Dexamethasone pharmacokinetics in the inner ear: comparison and use of facilitation agents. Otolaryngol Head Neck Surg. 2000;122(4):521–8.PubMedGoogle Scholar
  15. 15.
    McRackan TR, Best J, Pearce EC, Bennett ML, Dietrich M, Wanna GB, Haynes DS, Labadie RF. Intratympanic dexamethasone as a symptomatic treatment for Meniere’s disease. Otol Neurotol. 2014;35(9):1638–40.CrossRefGoogle Scholar
  16. 16.
    Thomsen J, Bretlau P, Tos M, et al. Placebo effect in surgery for Ménière’s disease. A double-blind, placebo-controlled study on endolymphatic sac shunt surgery. Arch Otolaryngol. 1981;107(5):271.CrossRefGoogle Scholar
  17. 17.
    Glasscock ME, et al. What I think of sac surgery in 1989. Am J Otol. 1989;10(3):230–3.PubMedGoogle Scholar
  18. 18.
    Pillsbury HC 3rd, Arenberg IK, Ferraro J, Ackley RS. Endolymphatic sac surgery. The Danish sham surgery study: an alternative analysis. Otolaryngol Clin N Am. 1983;16(1):123–7.Google Scholar
  19. 19.
    Welling DB, Nagaraja HN. Endolymphatic mastoid shunt: a reevaluation of efficacy. Otolaryngol Head Neck Surg. 2000;122(3):340.CrossRefGoogle Scholar
  20. 20.
    Telischi FF, Luxford WM. Long-term efficacy of endolymphatic sac surgery for vertigo in Ménière’s disease. Otolaryngol Head Neck Surg. 1993;109(1):83.CrossRefGoogle Scholar
  21. 21.
    Kato BM, LaRouere MJ, Bojrab DI, et al. Evaluating quality of life after endolymphatic sac surgery: the Meniere’s disease outcomes questionnaire. Otol Neurotol. 2004;25:339–44.CrossRefGoogle Scholar
  22. 22.
    Sood A, Lambert P, et al. Endolymphatic sac surgery for Meniere’s disease: a systematic review and meta-analysis. Otol Neurotol. 2014;35:1033Y1045.CrossRefGoogle Scholar
  23. 23.
    Paparella MM. Revision of endolymphatic sac surgery for recurrent Meniere’s disease. Otolaryngol Clin North Am. 2002;35(3):607–19.CrossRefGoogle Scholar
  24. 24.
    Paparella MM1, Sajjadi H. Endolymphatic sac revision for recurrent Menière’s disease. Am J Otol. 1988;9(6):441–7.PubMedGoogle Scholar
  25. 25.
    Fowler EP. Streptomycin treatment for vertigo. Trans Am Acad Ophthalmol Otolaryngol. 1948;52:293–301.PubMedGoogle Scholar
  26. 26.
    Ohmori WH. Mechano-electrical transduction currents in isolated vestibular hair cells of the chick. J Physiol. 1985;359:189–217.CrossRefGoogle Scholar
  27. 27.
    Waguespack J, Ricci A. Aminoglycoside ototoxicity: permeant drugs cause permanent hair cell loss. J Physiol. 2005;567:359–60.CrossRefGoogle Scholar
  28. 28.
    Williams S, Zenner H, Schacht J. Three molecular steps of aminoglycoside ototoxicity demonstrated in outer hair cells. Hear Res. 1987;30:11–8.CrossRefGoogle Scholar
  29. 29.
    Schuknecht HP. Ablation therapy for the relief of Meniere’s disease. Laryngoscope. 1956;66:859.CrossRefGoogle Scholar
  30. 30.
    Graham MD, Sataloff RT, Kemink JL. Titration streptomycin therapy for bilateral Meniere’s disease: a preliminary report. Otolaryngol Head Neck Surg. 1984;92(4):440–7.CrossRefGoogle Scholar
  31. 31.
    Magnusson M, Padoan S. Delayed onset of ototoxic effects of gentamicin in treatment of Menière’s disease. Rationale for extremely low dose therapy. Acta Otolaryngol. 1991;111(4):671–6.CrossRefGoogle Scholar
  32. 32.
    Nedzelski J, Chiong C, Fradet G, et al. Intratympanic gentamicin instillation as treatment of unilateral Meniere’s disease: update of an ongoing study. Am J Otol. 1993;13:278–82.Google Scholar
  33. 33.
    Prezant TR, Agapian JV, Bohlman MC, Bu X, Oztas S, Qiu WQ, Arnos KS, Cortopassi GA, Jaber L, Rotter JI. Mitochondrial ribosomal RNA mutation associated with both antibiotic-induced and non-syndromic deafness. Nat Genet. 1993;4(3):289–94.CrossRefGoogle Scholar
  34. 34.
    Minor LB. Intratympanic gentamicin for control of vertigo in Meniere’s disease: vestibular signs that specify completion of therapy. Am J Otol. 1999;20(2):209.PubMedGoogle Scholar
  35. 35.
    Kaplan DM, Nedzelski JM, Chen JM, et al. Intratympanic gentamicin for the treatment of unilateral Meniere’s disease. Laryngoscope. 2000;110(8):1298.CrossRefGoogle Scholar
  36. 36.
    Dandy WE. Ménière’s disease: its diagnosis and method of treatment. Arch Surg. 1928;16:1127–52.CrossRefGoogle Scholar
  37. 37.
    Dandy WE. Treatment of Ménière’s disease by section of only the vestibular portion of the acoustic nerve. Bull Johns Hopkins Hosp. 1933;53:52–5.Google Scholar
  38. 38.
    House WF. Surgical exposure of the internal auditory canal and its contents through the middle cranial fossa. Laryngoscope. 1961;71:1363.CrossRefGoogle Scholar
  39. 39.
    Silverstein H, Norrell H. Retrolabyrinthine surgery: a direct approach to the cerebellopontine angle. Otolaryngol Head Neck Surg. 1980;88:462–9.CrossRefGoogle Scholar
  40. 40.
    Rosenberg S, Silverstein H, Hoffer M, et al. Hearing results after posterior fossa vestibular neurectomy. Otolaryngol Head Neck Surg. 1996;114:32–7.CrossRefGoogle Scholar
  41. 41.
    Silverstein H, Norrell H, Smouha EE. Retrosigmoid-internal auditory canal approach vs. retrolabyrinthine approach for vestibular neurectomy. Otolaryngol Head Neck Surg. 1987;97(3):300–7.CrossRefGoogle Scholar
  42. 42.
    Tewary AK, Riley N, Kerr AG. Long-term results of vestibular nerve section. J Laryngol Otol. 1998;112(12):1150–3.CrossRefGoogle Scholar
  43. 43.
    Pappas DG Jr, Pappas DG Sr. Vestibular nerve section: long-term follow-up. Laryngoscope. 1997;107(9):1203–9.CrossRefGoogle Scholar
  44. 44.
    Silverstein H, Norrell H, Rosenberg S. The resurrection of vestibular neurectomy: a 10-year experience with 115 cases. J Neurosurg. 1990;72(4):533–9.CrossRefGoogle Scholar
  45. 45.
    Silverstein H, Jackson LE. Vestibular nerve section. Otolaryngol Clin N Am. 2002;35(3):655–73. ISSN 0030-6665CrossRefGoogle Scholar
  46. 46.
    Setty BS, et al. Fully endoscopic Retrosigmoid vestibular nerve section for refractory Meniere disease. J Neurol Surg B. 2016;77(04):341–9.CrossRefGoogle Scholar
  47. 47.
    House JW, Brackmann DE. Tinnitus: surgical management. Ciba Found Symp. 1981;85:204–16.PubMedGoogle Scholar
  48. 48.
    Hammerschlag PE, Schuknecht HF. Transcanal labyrinthectomy for intractable vertigo. Arch Otolaryngol. 1981;107:152–6.CrossRefGoogle Scholar
  49. 49.
    Graham MD. Transmastoid labyrinthectomy: further experiences with the indications, complications, and early postoperative results. J Laryngol Otol. 1981;95:1205–11.CrossRefGoogle Scholar
  50. 50.
    Kemink JL, Telian SA, Graham MD, Joynt L. Transmastoid labyrinthectomy: reliable surgical management of vertigo. Otolaryngol Head Neck Surg. 1989;101(1):5–10.CrossRefGoogle Scholar
  51. 51.
    Zwolan TA, Shepard NT, Niparko JK. Labyrinthectomy with cochlear implantation. Am J Otol. 1993;14(3):220–3.PubMedGoogle Scholar
  52. 52.
    MacKeith SA, Bottrill ID, Ramsden JD. Simultaneous labyrinthectomy with cochlear implantation in patients with bilateral Ménière’s disease. Ann Otol Rhinol Laryngol. 2014;123(7):485–9.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Neal M. Jackson
    • 1
  • Michael J. LaRouere
    • 1
  1. 1.Department of Neurotology, Providence HospitalMichigan Ear InstituteFarmington HillsUSA

Personalised recommendations